TY - JOUR
T1 - Novel activating mutations lacking cysteine in type i cytokine receptors in acute lymphoblastic leukemia
AU - Shochat, Chen
AU - Tal, Noa
AU - Gryshkova, Vitalina
AU - Birger, Yehudit
AU - Bandapalli, Obul R.
AU - Cazzaniga, Giovanni
AU - Gershman, Nava
AU - Kulozik, Andreas E.
AU - Biondi, Andrea
AU - Mansour, Marc R.
AU - Twizere, Jean Claude
AU - Muckenthaler, Martina U.
AU - Ben-Tal, Nir
AU - Constantinescu, Stefan N.
AU - Bercovich, Dani
AU - Izraeli, Shai
PY - 2014/7/3
Y1 - 2014/7/3
N2 - Gain-of-function somatic mutations introducing cysteines to either the extracellular or to the transmembrane domain (TMD) in interleukin-7 receptor a (IL7R) or cytokine receptor like factor 2 (CRLF2) have been described in acute lymphoblastic leukemias. Here we report noncysteine in-frame mutations in IL7R and CRLF2 located in a region of the TMD closer to the cytosolic domain. Biochemical and functional assays showed that these are activating mutations conferring cytokine-independent growth of progenitor lymphoid cells in vitro and are transforming in vivo. Protein fragment complementation assays suggest that despite the absence of cysteines, the mechanism of activation is through ligand-independent dimerization. Mutagenesis experiments and ConSurf calculations suggest that the mutations stabilize the homodimeric conformation, positioning the cytosolic kinases in predefined orientation to each other, thereby inducing spontaneous receptor activation independently of external signals. Hence, type I cytokine receptors may be activated in leukemia through 2 types of transmembrane somatic dimerizing mutations.
AB - Gain-of-function somatic mutations introducing cysteines to either the extracellular or to the transmembrane domain (TMD) in interleukin-7 receptor a (IL7R) or cytokine receptor like factor 2 (CRLF2) have been described in acute lymphoblastic leukemias. Here we report noncysteine in-frame mutations in IL7R and CRLF2 located in a region of the TMD closer to the cytosolic domain. Biochemical and functional assays showed that these are activating mutations conferring cytokine-independent growth of progenitor lymphoid cells in vitro and are transforming in vivo. Protein fragment complementation assays suggest that despite the absence of cysteines, the mechanism of activation is through ligand-independent dimerization. Mutagenesis experiments and ConSurf calculations suggest that the mutations stabilize the homodimeric conformation, positioning the cytosolic kinases in predefined orientation to each other, thereby inducing spontaneous receptor activation independently of external signals. Hence, type I cytokine receptors may be activated in leukemia through 2 types of transmembrane somatic dimerizing mutations.
UR - http://www.scopus.com/inward/record.url?scp=84903948818&partnerID=8YFLogxK
U2 - 10.1182/blood-2013-10-529685
DO - 10.1182/blood-2013-10-529685
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 24787007
AN - SCOPUS:84903948818
SN - 0006-4971
VL - 124
SP - 106
EP - 110
JO - Blood
JF - Blood
IS - 1
ER -